<DOC>
	<DOC>NCT02247349</DOC>
	<brief_summary>The purpose of this study is to determine the safety, tolerability, pharmacokinetics, immunogenicity, antitumor activity and pharmacodynamics of BMS-986012 alone and in combination with nivolumab in patients with relapsed/refractory SCLC.</brief_summary>
	<brief_title>BMS-986012 in Relapsed/Refractory SCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Histological or cytological confirmed small cell lung cancer (SCLC) Performance Status 01 Adequate organ function Measurable disease Known or suspected brain metastasis Small cell cancer not lung in origin Significant or acute medical illness Uncontrolled or significant cardiac disease Infection â‰¥ Grade 2 peripheral neuropathy Concomitant malignancies HIV related disease or known or suspected HIV+ Hepatitis B or C infection ECG abnormalities as defined by the protocol Allergies or hypersensitivities to monoclonal antibodies, BMS986012 or related compounds, including fucosylGM1 vaccine and Nivolumab Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>